Cellular Vehicles

About Cellular Vehicles

Cellular Vehicles develops the Odyssey System, which automates and standardizes the preparation and administration of Cell Gene Therapy doses at healthcare facilities. This technology increases the capacity for healthcare providers to deliver curative cell-based therapies, addressing the infrastructure gap in the rapidly growing cell therapy market.

```xml <problem> The cell and gene therapy (CGT) field faces infrastructure limitations in dose preparation and administration, hindering the scalability and accessibility of these advanced treatments. Manual processes are prone to variability, limiting the number of healthcare providers capable of delivering CGTs and potentially delaying patient access to curative therapies. </problem> <solution> Cellular Vehicles develops the Odyssey System, an automated platform designed to standardize and streamline cell and gene therapy dose preparation at the point of care. The system automates critical steps such as thawing, washing, and dosing, reducing manual handling and variability. By simplifying the "last mile" of CGT delivery, the Odyssey System increases the capacity of healthcare facilities to administer these therapies, enabling wider patient access. The platform aims to accelerate the transition to curative cell-based therapies by addressing key infrastructure bottlenecks in the CGT supply chain. </solution> <features> - Automated thawing, washing, and dosing of cell and gene therapies - Standardized dose preparation protocols to minimize variability - Integrated system designed for hospital-side deployment - Modular design to accommodate various CGT products and workflows - Closed system to maintain sterility and minimize contamination risk </features> <target_audience> The primary target audience includes hospitals, healthcare providers, and biopharmaceutical companies involved in the delivery of cell and gene therapies. </target_audience> ```

What does Cellular Vehicles do?

Cellular Vehicles develops the Odyssey System, which automates and standardizes the preparation and administration of Cell Gene Therapy doses at healthcare facilities. This technology increases the capacity for healthcare providers to deliver curative cell-based therapies, addressing the infrastructure gap in the rapidly growing cell therapy market.

Where is Cellular Vehicles located?

Cellular Vehicles is based in San Francisco, United States.

When was Cellular Vehicles founded?

Cellular Vehicles was founded in 2021.

How much funding has Cellular Vehicles raised?

Cellular Vehicles has raised 500000.

Location
San Francisco, United States
Founded
2021
Funding
500000
Employees
8 employees
Major Investors
MedTech Innovator

Find Investable Startups and Competitors

Search thousands of startups using natural language

Cellular Vehicles

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Cellular Vehicles develops the Odyssey System, which automates and standardizes the preparation and administration of Cell Gene Therapy doses at healthcare facilities. This technology increases the capacity for healthcare providers to deliver curative cell-based therapies, addressing the infrastructure gap in the rapidly growing cell therapy market.

cellularvehicles.com700+
cb
Crunchbase
Founded 2021San Francisco, United States

Funding

$

Estimated Funding

$500K+

Major Investors

MedTech Innovator

Team (5+)

No team information available.

Company Description

Problem

The cell and gene therapy (CGT) field faces infrastructure limitations in dose preparation and administration, hindering the scalability and accessibility of these advanced treatments. Manual processes are prone to variability, limiting the number of healthcare providers capable of delivering CGTs and potentially delaying patient access to curative therapies.

Solution

Cellular Vehicles develops the Odyssey System, an automated platform designed to standardize and streamline cell and gene therapy dose preparation at the point of care. The system automates critical steps such as thawing, washing, and dosing, reducing manual handling and variability. By simplifying the "last mile" of CGT delivery, the Odyssey System increases the capacity of healthcare facilities to administer these therapies, enabling wider patient access. The platform aims to accelerate the transition to curative cell-based therapies by addressing key infrastructure bottlenecks in the CGT supply chain.

Features

Automated thawing, washing, and dosing of cell and gene therapies

Standardized dose preparation protocols to minimize variability

Integrated system designed for hospital-side deployment

Modular design to accommodate various CGT products and workflows

Closed system to maintain sterility and minimize contamination risk

Target Audience

The primary target audience includes hospitals, healthcare providers, and biopharmaceutical companies involved in the delivery of cell and gene therapies.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.